AuditorJun 15, 2026, 04:47 PM
Coherus Oncology Changes Auditor from EY to PwC
AI Summary
Coherus Oncology, Inc. dismissed Ernst & Young LLP as its independent registered public accounting firm on June 12, 2026. The company subsequently appointed PricewaterhouseCoopers LLP to serve as its new auditor for the fiscal year ending December 31, 2026. EY's previous reports for 2024 and 2025 did not contain adverse opinions, though a material weakness in internal controls was noted for 2024, which was remediated by 2025.
Key Highlights
- Coherus Oncology dismissed Ernst & Young LLP as its independent auditor on June 12, 2026.
- PricewaterhouseCoopers LLP was appointed as the new independent auditor for fiscal year 2026.
- EY's reports for fiscal years 2024 and 2025 contained no adverse opinions or disclaimers.
- A material weakness in internal control over financial reporting was reported for 2024.
- The material weakness was remediated by the end of fiscal year 2025.
- No disagreements with EY on accounting principles or practices were reported.
- No consultations with PwC on specific accounting matters occurred prior to appointment.
Price Impact
More from CHRS